Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34269581/
doi: 10.1021/acs.jmedchem.1c00439. Online ahead of print. 1 Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States. 2 Department of Medicine, College of Medicine, University...
Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34269847/
doi: 10.1007/s00262-021-03002-6. Online ahead of print. 1 Department of Radiation Oncology, University Hospital Tuebingen, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany. 2 Interfaculty Institute for Cell Biology, Department of Immunology,...
Total thiol can contribute to differentiating prostate cancer from BPH: Prostate Thiol Index as a new player - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34270802/
To assess the distinctiveness of serum native thiol (NT), total thiol (TT) and disulfide (SS) levels in PCa patients, we created a new parameter, prostate thiol index (PTI) [tPSA (TTxPVxAge)...
Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34235090/
doi: 10.3389/fonc.2021.708595. 1 Department of Urology, LMU Klinikum, Ludwig-Maximilians University Munich, Munich, Germany. 2 Department of Radiation Oncology, LMU Klinikum, Ludwig-Maximilians University Munich, Munich, Germany. 3 Department of Therapeutic Radiology...
Can Tumour Volume Percentage in Radical Prostatectomy Predict Cancer Biochemical Recurrence? Determining a Cut-off Point and Composite Risk Factors Approach - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34235101/
TVP can be used as an independent predictor of BCR after radical prostatectomy for prostate cancer. TVP cut-point of ≥8% allows the best discrimination. TVP should be considered in combination...